Alternative Name: | Ki-1, TNFRSF 8 |
|
MW: | ~110 kDa observed (SDS-PAGE) |
|
Source: | Produced in HEK 293 cells. The cysteine-rich region of human CD30 (Ki-1) (aa 1-380) is fused to the Fc portion of human IgG1 . |
|
UniProt ID: | P28908 |
|
Concentration: | 1mg/ml after reconstitution. |
|
Formulation: | Lyophilized. Contains PBS. |
|
Purity: | ≥95% (SDS-PAGE) |
|
Endotoxin Content: | <0.1EU/µg purified protein (LAL test; Bio Whittaker). |
|
Specificity: | Binds human CD30L (CD153). |
|
Applications: | ELISA
|
|
Application Notes: | ELISA: binds to CD30L. Can be used together with anti-human IgG1 PAb to detect membrane-bound human CD30L. |
|
Reconstitution: | Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein. |
|
Shipping: | Shipped on Blue Ice |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Stable for at least 6 months after receipt when stored at -20°C. |
|
Handling: | Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C. |
|
Scientific Background: | The CD30 receptor (CD30, Ki-1) is a member of the tumor necrosis factor receptor (TNF-R) family. CD30 is a type I transmembrane receptor, it contains 6 extracellular cysteine-rich motifs, is shed by the TNFα-converting enzyme and is associated with the Reed-Sternberg cells of Hodgkins disease as well as with T cells and some lymphomas. Activated CD30 recruits TNF receptor-associated factor 1, 2, 3 and 5. CD30-CD30L have been reported to be involved in costimulation of T cell proliferation, induction of HIV expression, negative selection and apoptosis as well as in diabetes and several allergic, viral and autoimmune diseases. |
|
Regulatory Status: | RUO - Research Use Only |
|